🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. ALN-4285

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  2. ALN-4915

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  3. ALN-5288

    Alnylam Netherlands B.V.

    Alzheimer's Disease

    phase 1 small molecule active

    1 trial

  4. ALN-AAT

    Alnylam Netherlands B.V.

    Antitrypsin Deficiency Liver Disease

    phase 1 small molecule terminated

    1 trial

  5. ALN-AGT01

    Alnylam Netherlands B.V.

    Hypertension

    phase 1 small molecule completed

    1 trial

  6. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  7. ALN-APP

    Alnylam Netherlands B.V.

    Early-Onset Alzheimer Disease

    phase 1 small molecule active

    1 trial

  8. ALN-BCAT

    Alnylam Netherlands B.V.

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  9. ALN-HBV

    Alnylam Netherlands B.V.

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  10. ALN-HSD

    Alnylam Netherlands B.V.

    Nonalcoholic Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  11. ALN-HTT02

    Alnylam Netherlands B.V.

    Huntington's Disease

    phase 1 small molecule active

    1 trial

  12. ALN-PCS02

    Alnylam Netherlands B.V.

    Elevated LDL-Cholesterol (LDL-C)

    phase 1 small molecule completed

    1 trial

  13. ALN-PCSSC

    Alnylam Netherlands B.V.

    Hypercholesterolemia

    phase 1 small molecule completed

    1 trial

  14. ALN-TTR01

    Alnylam Netherlands B.V.

    Transthyretin Mediated Amyloidosis (ATTR)

    phase 1 small molecule completed

    1 trial

  15. ALN-TTR02

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  16. ALN-TTRSC (revusiran)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  17. ALN-TTRSC02

    Alnylam Netherlands B.V.

    Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

    phase 1 small molecule completed

    1 trial

  18. ALN-TTRSC04

    Alnylam Netherlands B.V.

    Transthyretin-Mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  19. ALN-VSP02

    Alnylam Netherlands B.V.

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  20. AMX0114

    Amylyx Pharmaceuticals EMEA B.V.

    ALS

    phase 1 small molecule active

    1 trial

  21. ASTX727, ASTX727, Decitabine, ASTX727

    Taiho Pharma Netherlands B.V.

    Myelodysplastic Syndromes (MDS)

    phase 1 small molecule active

    1 trial

  22. Ablation procedure and/or cardioversion

    Rhythm Pharmaceuticals Netherlands B.V.

    Atrial Fibrillation

    phase 1 other completed

    1 trial

  23. An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 1 other active

    1 trial

  24. An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function

    Pharming Technologies B.V.

    Activated Phosphoinositide 3-Kinase Delta Syndrome

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources